Image source: Getty Images.
What: Biogen (NASDAQ: BIIB) is down 12% at 1:15 p.m. EDT Tuesday after the biotech reported that opicinumab, one of its most lucrative pipeline drugs, failed a phase 2 clinical trial.
Image source: Getty Images.
What: Biogen (NASDAQ: BIIB) is down 12% at 1:15 p.m. EDT Tuesday after the biotech reported that opicinumab, one of its most lucrative pipeline drugs, failed a phase 2 clinical trial.